Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Miller

Internal Medicine Lynchburg, VA Medical Doctor

NPI 1720062938 CMS profile 123717

1922 Thomson Dr Ste B, Lynchburg, VA 24501

Open in the dashboard

General payments

$6,528

396 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Miller of Lynchburg, VA is reported in the CMS Open Payments database as having received $6,528 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $288 13
2024 General $721 34
2023 General $1,176 65
2022 General $776 60
2021 General $1,739 115
2020 General $791 59
2019 General $1,037 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Miller
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Miller were reported at $288. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Miller Internal Medicine median Middle half National median
2019 $1,037 $159 $48–$570 $163
2020 $791 $119 $33–$402 $114
2021 $1,739 $135 $37–$521 $132
2022 $776 $141 $42–$496 $149
2023 $1,176 $149 $45–$519 $160
2024 $721 $154 $47–$537 $164
2025 $288 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,064 88 payments
  2. Novo Nordisk Inc $954 55 payments
  3. Amgen Inc. $608 33 payments
  4. Janssen Pharmaceuticals, Inc $490 21 payments
  5. AstraZeneca Pharmaceuticals LP $373 23 payments
  6. Lilly USA, LLC $321 16 payments
  7. Biohaven Pharmaceuticals, Inc. $270 19 payments
  8. Esperion Therapeutics, Inc. $225 14 payments
  9. Pfizer Inc. $198 12 payments
  10. Astellas Pharma US Inc $188 11 payments
  11. Other $1,836 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,495 392 payments
  2. Education $33 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $531 36 payments
  2. UBRELVY $488 36 payments
  3. RYBELSUS $472 33 payments
  4. VRAYLAR $401 34 payments
  5. Repatha $369 22 payments
  6. XARELTO $337 19 payments
  7. NURTEC ODT $305 21 payments
  8. Otezla $259 17 payments
  9. FARXIGA $247 15 payments
  10. AIMOVIG $230 13 payments
  11. Other $4,598 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

6,274

Median for Internal Medicine: 777

Drug cost

$569,218

Median for Internal Medicine: $73,373

Branded share of claims

15.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 75 $105,562
Eliquis Apixaban Brand 58 $73,041
Januvia Sitagliptin Phosphate Brand 49 $55,486
Dupixent Syringe Dupilumab Brand 12 $52,997
Xarelto Rivaroxaban Brand 35 $42,788
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $31,512
Mounjaro Tirzepatide Brand 23 $25,281
Trulicity Dulaglutide Brand 16 $21,491
Farxiga Dapagliflozin Propanediol Brand 20 $20,513
Repatha Sureclick Evolocumab Brand 29 $18,109

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$162,239

Of which drugs: $105

Medicare patients

462

Average age 76

Services billed

3,366

271 women, 191 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 40%
Arthritis 39%
Ischemic heart disease 19%
Atrial fibrillation 17%
Chronic kidney disease 14%
Depression 13%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 105 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $76
$76 — —
ZEPBOUND
  • Lilly USA, LLC $69
$69 — —
Ozempic
  • Novo Nordisk Inc $60
$60 75 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $49
$49 — —
RYBELSUS
  • Novo Nordisk Inc $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record